Panmure Gordon is Appointed as Nominated Adviser and Broker
Released: 6th December 2007

Released: 30th October 2007

Released: 30th October 2007 

Phase I Clinical Trial in Parkinson's disease and Acne programme commences 

Released 23rd October 2007

Summit receives £220,000
Summit receives £220,000 from UK Duchenne Muscular Dystrophy Charity
Released: 2nd October 2007  

Summit Presents Zebrafish Data
Summit Presents Zebrafish Data at the 7th Annual Meeting of the Safety Pharmacology Society
Released: 24th September 2007  

Zebrafish data supports MHRA Application
Zebrafish data supports new drug candidate moving into human clinical trials.
Released: 8th August 2007

Collaboration with European biotechnology company Evolva

Released: 24th July 2007

Released: 20th July 2007

Released: 19th July 2007

VASTox Announces Significant Progress in Pharmaceutical Services Business
Pilot screening deals signed with Merck and J&J plus construction of GMP carbohydrate chemistry facility completed.
Released: 27th June 2007

VASTox Receives Grant Worth £400,000 to Support R&D at Carbohydrate Chemistry Facility
Grant awarded by Welsh Development Agency.
Released: 20th June 2007

Preliminary Results for Year Ended 31 January 2007
Click for webcast presentation.
Released: 29th May 2007

VASTox Prepares to Commence the Next Stage of Clinical Trials in Parkinson's Programmes
Progress follows on from earlier positive clinical data.
Released: 23rd May 2007

VASTox Signs Carbohydrate Service Deal which Includes $450,000 Development Payment and 5% Royalty Fee
Deal signed with undisclosed US pharmaceutical company.
Released: 16th May 2007

VASTox Selects Preclinical Candidate in Duchenne Muscular Dystrophy Programme
SUMM C1100 selected as candidate to advance into preclinical development.
Released: 8th May 2007

VASTox to Present Data from Duchenne Muscular Dystrophy Programme at Conference
VASTox attending leading international DMD conference in Ottawa, May 3-5 2007.
Released: 30th April 2007

VASTox Announce Positive Results in TB Programme
VASTox identifies novel compounds that kill tuberculosis bacteria.
Released: 25th April 2007

VASTox Appoints George Elliott to the Board of Directors
Mr Elliott appointed Non-executive Director and Chairman of the Audit Committee.
Released: 23rd April 2007

VASTox Consolidate Market Dominance in Zebrafish Chemical Genomics Following the Granting of a Key Patent
VASTox granted a European patent that increases the value of the zebrafish chemical genomics technology platform.
Released: 17th April 2007

Patent Granted in the US to Strengthen DMD Programme
VASTox's unique approach to treating DMD has been further protected by the award of this patent by the US Patent Office.
Released: 12th April 2007

Major Pharmaceutical Companies Present VASTox Scientific Data at International Conference
Roche, Bayer-Schering and Merz present predictive toxicology data acquired using VASTox's zebrafish technology platform.
Released: 27th March 2007

VASTox Complete the Simultaneous Acquisitions of DanioLabs Ltd and Dextra Laboratories Ltd
Drug discovery pipeline enhanced through acquisitions and VASTox becomes world dominant in two drug discovery technology platforms.
Released: 22nd March 2007

VASTox Sign Two Research Collaboration Deals Worth a Combined Total of €1.0 Million
VASTox has signed deals with the multinational pharmaceutical company Rottapharm and an undisclosed European biotechnology company which will leverage off the Company's technology platform.
Released: 13th February 2007

Pre-close Trading Statement
VASTox releases a pre-close trading statement ahead of the preliminary results announcement on 22 May 2007.
Released: 30th January 2007

VASTox Joins Research Consortium to Develop New Treatments for Cancer
Research consortium backed by €2 million grant from the European Commission to focus on cancer stem cells as target for the development of new therapies.
Released: 17th January 2007